Tian Hua, Ge Chao, Zhao Fangyu, Zhu Miaoxin, Zhang Lin, Huo Qi, Li Hong, Chen Taoyang, Xie Haiyang, Cui Ying, Yao Ming, Li Jinjun
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, 25/Ln 2200, Xietu Road, Shanghai 200032, China.
Qi Dong Liver Cancer Institute, Qi Dong 226200, Jiangsu Province, China.
Carcinogenesis. 2017 Feb 1;38(2):207-217. doi: 10.1093/carcin/bgw125.
Increasing evidence has shown that zinc-alpha2-glycoprotein (AZGP1) is associated with the progression and prognosis of several tumor types. However, little is known regarding the underlying molecular mechanisms of AZGP1 in hepatocellular carcinoma (HCC). In this study, we report that transcription factor Ikaros bound to the AZGP1 promoter and increased its expression in HCC cells. The downregulation of AZGP1 was associated with histone deacetylation in HCC. In addition, the positive feedback regulation via acetylation of histone H4-mediated transactivation of the Ikaros promoter and the Ikaros-mediated transactivation of the acetylation of histone H4 were crucial for regulating AZGP1 expression in HCC cells. Moreover, low serum AZGP1 level in HCC patients was associated with poor prognosis. The ectopic overexpression of AZGP1 or recombinant AZGP1 protein inhibited HCC cell proliferation, migration and invasion in vitro and in vivo, whereas silencing AZGP1 expression resulted in increased cell proliferation, migration and invasion in vitro. In addition, we found that AZGP1 inhibited cell migration and invasion through the regulation of the PTEN/Akt and CD44s pathways. Collectively, our findings revealed the molecular mechanism of AZGP1 expression in HCC, providing new insights into the mechanisms underlying tumor progression.
越来越多的证据表明,锌-α2-糖蛋白(AZGP1)与多种肿瘤类型的进展和预后相关。然而,关于AZGP1在肝细胞癌(HCC)中的潜在分子机制知之甚少。在本研究中,我们报道转录因子Ikaros与AZGP1启动子结合并增加其在肝癌细胞中的表达。HCC中AZGP1的下调与组蛋白去乙酰化有关。此外,通过组蛋白H4乙酰化介导的Ikaros启动子反式激活以及Ikaros介导的组蛋白H4乙酰化反式激活的正反馈调节对于调节HCC细胞中AZGP1的表达至关重要。此外,HCC患者血清中低水平的AZGP1与不良预后相关。AZGP1的异位过表达或重组AZGP1蛋白在体外和体内均抑制HCC细胞的增殖、迁移和侵袭,而沉默AZGP1表达则导致体外细胞增殖、迁移和侵袭增加。此外,我们发现AZGP1通过调节PTEN/Akt和CD44s途径抑制细胞迁移和侵袭。总的来说,我们的研究结果揭示了HCC中AZGP1表达的分子机制,为肿瘤进展的潜在机制提供了新的见解。